SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Head And Neck Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Head And Neck Cancer.

SGLT2i Better Than Diuretic for Early Decongestion in Acute Heart Failure?

Starting dapagliflozin (Farxiga) early during acute heart failure hospitalization didn’t boost decongestion, although it appeared to spare loop diuretic doses and increase diuresis compared with

April 3, 2024

Is social media derailing our teens? Study unveils the balancing act for adolescent wellbeing

Study delves into the varying impacts of social media on adolescents, distinguishing between healthy, unhealthy, and dependent usage while highlighting a spectrum of personal, interpersonal,

October 4, 2023

Biden’s Checkup; Sanjay Gupta Says Prez Should Get Cognitive Test; July 4 Injuries

Note that some links may require registration or subscription. The White House said President Biden did not take cold medicine before last week’s debate, shutting

July 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.